Pharma BD Deal Intelligence
Bayer exercised its first option under a 2019 multi-program research collaboration with Dewpoint Therapeutics (announced Oct 24, 2024) to license a precision-medicine program for genetic dilated cardiomyopathy (DCM) — a severe form driven by disease-associated biomolecular condensates, with early-onset heart failure and life-threatening arrhythmias. Per both companies' releases, Dewpoint is eligible for an upfront payment plus development and commercial milestones totaling an estimated $424 million, excluding royalties; the upfront/milestone split was not disclosed. The program pairs Dewpoint's biomolecular-condensate platform with Bayer's small-molecule R&D. In August 2025 Dewpoint restructured sharply — cutting ~70% of its ~130 staff, closing its Frankfurt and Dresden sites, and refocusing on oncology lead DPTx3186 (beta-catenin inhibitor) — but the Bayer-partnered DCM program was explicitly retained and remains active (preclinical/Phase 1-2) on Dewpoint's pipeline, underscoring its standing as a funded, partner-owned asset.